Stuart Schreiber’s bid to tackle huge class of crucial proteins nabs another $50M
Four years after launching with prestigious co-founders and ambitions to go after a family of ancient and crucial proteins, it’s still not clear how far Jnana Therapeutics has advanced. But it’s pushed far enough that investors are willing to infuse more cash.
Jnana announced a $50 million Series B on Wednesday led by RA Capital. Although light compared to the megarounds that have become increasingly routine for biotechs, it contains the same melange of A-list investors that backed the company’s scientists from the beginning, including Polaris, Versant, AbbVie and Pfizer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
